[Involvement of endothelin in the pathogenesis of hypertension and hypertensive target-organ damage].
Kanno
Kazuo
K
Division of Endocrinology and Metabolism, Musashino Red Cross Hospital.
Hirata
Yukio
Y
D000818:Animals; D000959:Antihypertensive Agents / Q000627:therapeutic use; D016282:Aspartic Acid Endopeptidases / Q000037:antagonists & inhibitors / Q000502:physiology; D000077300:Bosentan; D015195:Drug Design; D065128:Endothelin Receptor Antagonists; D000072396:Endothelin-Converting Enzymes; D016232:Endothelins / Q000378:metabolism / Q000502:physiology*; D006801:Humans; D006973:Hypertension / Q000188:drug therapy / Q000209:etiology*; D008666:Metalloendopeptidases; D017466:Receptors, Endothelin / Q000502:physiology*; D013449:Sulfonamides / Q000627:therapeutic use; D014661:Vasoconstriction
D000959:Antihypertensive Agents; D065128:Endothelin Receptor Antagonists; D016232:Endothelins; D017466:Receptors, Endothelin; D013449:Sulfonamides; D016282:Aspartic Acid Endopeptidases; D008666:Metalloendopeptidases; D000072396:Endothelin-Converting Enzymes; D000077300:Bosentan